Policy & Regulation
Innate Pharma reveals preliminary data from monalizumab and imfinzi study
17 May 2018 -

Preliminary data from Innate Pharma's (EPA: IPH) ongoing Phase I dose escalation and expansion study evaluating the safety and efficacy of the combination of monalizumab, a first-in-class monoclonal antibody targeting NK- and T cell checkpoint receptor NKG2A, with imfinzi (durvalumab), was announced by the company on Thursday.

According to the data, there was preliminary anti-tumour activity in patients with recurrent, metastatic colorectal cancer, with three partial responses and 11 stable disease responses out of the 37 patients evaluable for efficacy, and a disease control rate of 24% witnessed at 16 weeks.

A manageable toxicity profile was observed in the data.

The Phase I dose escalation and expansion study enrolled a total of 55 patients. The dose-escalation part involved 15 patients with selected solid tumours who received durvalumab 1500 mg every four weeks in combination with monalizumab at increasing doses. The expansion phase involved 40 patients with microsatellite-stable colorectal cancer (MSS-CRC), and 58% of these patients had received three or more lines of previous therapy.

Following these preliminary results, Innata Pharma's partner AstraZeneca (LON: AZN) and its global biologics research arm MedImmune have decided to progress the combination with standard of care therapies.



Related Headlines